Για να δείτε αναλυτικά τα περιεχόμενα του βιβλίου ή να το παραγγείλετε πατήστε εδώ…

Νέα μείωση τιμών για τα φάρμακα απαιτεί τώρα η Τρόικα. Διαφωνεί το υπουργείο Υγείας και ο ΕΟΦ

Σκληραίνουν οι διαπραγματεύσεις μεταξύ της ηγεσίας του υπουργείου Υγείας και της τρόικας για τα μέτρα που πρέπει να ληφθούν στον τομέα του φαρμάκου με στόχο την εξοικονόμηση 900 εκατομμυρίων ευρώ το 2012.

Κατά τη διάρκεια πολύωρης συνάντησης των δύο πλευρών, οι εκπρόσωποι της τρόικας εξέφρασαν επιφυλάξεις για την αποτελεσματικότητα των μέτρων που έχει λάβει  η ελληνική πλευρά και πρότειναν την εφαρμογή δραστικότερων λύσεων. Συγκεκριμένα, η Τρόικα  πιέζει για νέα οριζόντια μείωση στις τιμές των φαρμάκων κατά 15% και συνταγογράφηση  με βάση τη δραστική ουσία.

Hospitals hire reps to sell doctors on patient referrals

Kaiser Health News | Phil Galewitz

The University of Chicago Medical Center is one of a growing number of hospitals nationwide hiring former drug and device sales reps to visit doctors' offices to persuade them to use their services over competing facilities. Rather than handing out samples of prescription drugs, the sales reps call on doctors armed with the latest information on how their facility is reducing hospital-acquired infections and improving patient-satisfaction scores.

In visits that can last five to 20 minutes, reps try to win doctors' loyalty by helping them get better times on operating room schedules or easier patient referrals to hospital-based specialists. The sales reps can also carry messages back to the hospital, such as a doctor's request for a new medical device to be available in surgery.

Ο Φαρμακευτικός Σύλλογος Αττικής αύξησε τις εφημερίες των φαρμακείων

                                                       ΔΕΛΤΙΟ ΤΥΠΟΥ


Ο Φαρμακευτικός Σύλλογος Αττικής, διαισθανόμενος τις ολοένα αυξανόμενες ανάγκες των πολιτών για άμεση εξεύρεση των φαρμάκων τους κατά τις ώρες εφημεριών και διανυκτερεύσεων, αύξησε τις διημερεύσεις από 1/1/2012 σε ορισμένες περιοχές της Αττικής και από 1/2/2012 στις υπόλοιπες περιοχές, φτάνοντας σε τριπλασιασμό των περσινών εφημεριών.

Boehringer Ingelheim launches accelerated drug development programme

Boehringer Ingelheim has announced the launch of a new programme for accelerated drug product supply, leveraging its automated high throughput technologies.

The new Lean-to-Clinic scheme is able to deliver drug substances at competitive prices at a rapid rate, allying the company's BI-HEX high expression system with a streamlined development approach.

Designed for the production of monoclonal antibodies, it is a one-stop-shop service that can deliver drug substances for toxicological and clinical studies after only 13 months, while drug products for clinical studies can be produced within 16 months.

Simon Sturge, corporate senior vice-president for biopharmaceuticals at Boehringer Ingelheim, said this can help to accelerate cell line and phase I process development, as well as preclinical and clinical supplies from mammalian cell cultures.

"Lean-to-Clinic is another milestone of our winning offers strategy to secure technology leadership, flexibility and customer orientation," he added.

This comes after the company announced a new agreement to provide process development and clinical manufacturing services to Aveo Pharmaceuticals for the drug ficlatuzumab last month.

Amgen announces acquisition of Micromet

Amgen has announced plans to acquire the biotechnology company Micromet in a deal worth $1.16 billion (740 million pounds).

The takeover of the German-based company has been unanimously approved by both organisations' board of directors and will provide Amgen with rights to new facilities, products and technology platforms.

Included in the deal will be blinatumomab, a bispecific T-cell engager (BiTE) antibody in development for acute lymphoblastic leukaemia and non-Hodgkin's lymphoma, as well as the solid tumour therapy solitomab.

It will also encompass Micromet's proprietary BiTE antibody technology, an innovative platform that offers significant potential in future clinical research into multiple tumour types.

Kevin Sharer, chairman and chief executive officer (CEO) of Amgen, said: "Blinatumomab will serve as an important complement to our oncology pipeline and is representative of our corporate strategy, which is focused on developing and successfully commercialising therapeutics to treat patients with grievous illness."

Last month, it was announced that Mr Sharer will be stepping down as CEO in May 2012, when he will be succeeded by Robert Bradway.